| Literature DB >> 30551578 |
Bo Pan1, Haoxuan Yang2, Zhenzheng Wu3, Izhar Hyder Qazi4,5, Guoshi Liu6, Hongbing Han7, Qingyong Meng8, Guangbin Zhou9.
Abstract
This study aimed to investigate the effect of melatonin on the cell cycle of parthenogenetic embryos derived from vitrified mouse metaphase II (MII) oocytes. Fresh oocytes were randomly allocated into three groups: untreated (control), or vitrified by the open-pulled straw method without (Vitrification group) or with melatonin (MT) supplementation (Vitrification + MT group). After warming, oocytes were parthenogenetically activated and cultured in vitro, then the percentage of embryos in the G1/S phase, the levels of reactive oxygen species (ROS) and glutathione (GSH), and the mRNA expression of cell cycle-related genes (P53, P21 and E2F1) in zygotes and their subsequent developmental potential in vitro were evaluated. The results showed that the vitrification/warming procedures significantly decreased the frequency of the S phase, markedly increased ROS and GSH levels and the expression of P53 and P21 genes, and decreased E2F1 expression in zygotes at the G1 stage and their subsequent development into 2-cell and blastocyst stage embryos. However, when 10-9 mol/L MT was administered for the whole duration of the experiment, the frequency of the S phase in zygotes was significantly increased, while the other indicators were also significantly improved and almost recovered to the normal levels shown in the control. Thus, MT might promote G1-to-S progression via regulation of ROS, GSH and cell cycle-related genes, potentially increasing the parthenogenetic development ability of vitrified⁻warmed mouse oocytes.Entities:
Keywords: cell cycle; developmental potential; melatonin; mouse; oocyte vitrification; redox homeostasis
Mesh:
Substances:
Year: 2018 PMID: 30551578 PMCID: PMC6321189 DOI: 10.3390/ijms19124029
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Typical phase showing nucleolus status of parthenogenetic zygotes. After parthenogenetic activation of mouse MII oocytes followed by in vitro culture for 3 to 4 h, the resulting zygotes ((A) 3 h; (B) 4 h) were observed under a stereomicroscope for determination of their nucleolus status. The embryos with two separate pronuclei and no apparent nucleoli inside (white arrows) remained at the G1 stage, while those with apparent nucleoli (red arrows) had proceeded through the G1 into the S phase. In Figure 1A, the criterion of pronuclei of parthenogenetic zygote in G1 stage is shown in the white rectangle (zoomed-in frame of corresponding zygote with white asterisk). Similarly, in Figure 1B, the criterion of pronuclei of parthenogenetic zygote in the S stage is shown in the red rectangle (zoomed-in frame of corresponding zygote with red asterisk). Original magnification 200×.
Effect of melatonin on the G1/S transition in parthenogenetic zygotes.
| Groups | No. of Oocytes Vitrified | No. of Oocytes Recovered | No. of Oocytes with Normal Morphology (%) | No. of Oocytes Activated | No. of Activated Oocytes Developed to | |
|---|---|---|---|---|---|---|
| Zygotes in G1 Phase (%) | Zygotes in S Phase (%) | |||||
| Control | - | 126 | 126 (100 ± 0) a | 118 | 60 (50.85 ± 18.78) a | 58 (49.15 ± 18.78) a |
| Vitrification | 183 | 171 | 158 (87.68 ± 8.22) b | 155 | 113 (72.91 ± 10.89) b | 42 (27.09 ± 10.89) b |
| Vitrification + MT | 174 | 163 | 153 (89.59 ± 5.71) b | 141 | 84 (59.58 ± 8.74) a | 57 (40.42 ± 8.74) a |
Morphologically normal oocytes were evaluated by visual inspection of the membrane integrity, the zona pellucida (ZP), and any altered appearance of the cytoplasm (e.g., becoming white, colorless, or dispersed). The number of zygotes with nucleolus (S phase) or without nucleolus (G1 phase) was counted at 4 h after oocyte parthenogenetic activation (PA). Mouse MII oocytes from “Vitrification group” were first subjected to vitrification/warming and 1 h of in vitro culture, then to PA followed by in vitro culture of parthenogenetic embryos. During the whole experimental procedure, the other oocytes were treated either with 10−9 mol/L melatonin (MT) or without MT and vitrification/warming were classified as “Vitrification + MT group” and “Control group”, respectively. The experiment was replicated five times. The rate of oocytes with normal morphology (%) = (No. of oocytes with normal morphology/No. of oocytes recovered) × 100. The rate of zygotes in S stage (%) = (No. of zygotes in S stage/No. of oocytes activated) × 100. The values are shown as mean ± standard deviation (SD). Values with different superscripts (a and b) in the same column differ significantly (p < 0.05).
Figure 2Reactive oxygen species (ROS) levels in mouse MII oocytes and their parthenogenetic zygotes. The dynamic change of ROS levels in mouse oocytes and their parthenogenetic zygotes (A) ROS staining in oocytes (B,C) and their parthenogenetic zygotes (D) Fluorescence intensities were correlated with intracellular levels of ROS. Different superscripts (a and b) represent treatment differences within panels (p < 0.05). After warming, mouse MII oocytes were in vitro cultured for 0 h (Oocyte-IVC 0 h) or 1 h (Oocyte-IVC 1 h) in M2 medium. The oocytes cultured for 1 h were selected for parthenogenetic activation (PA). During the entire experiment, all the media were supplemented with 10−9 mol/L (Vitrification + MT group) or 0 mol/L melatonin (Vitrification group). Fresh oocytes without melatonin (MT) treatment were used as controls (Control group). After PA and in vitro culture for 3 h, the resulting zygotes (zygote-IVC 3 h) were used for ROS detection together with mouse oocytes before PA. The values (the relative ROS levels)) are shown as mean ± SEM. The experiment was replicated at least three times. Original magnification 200×.
Figure 3Glutathione (GSH) levels in mouse MII oocytes and their parthenogenetic zygotes. (A) The dynamic change of GSH levels in mouse oocytes and their parthenogenetic zygotes. (B) GSH staining of oocytes and their parthenogenetic zygotes in three groups. Fluorescence intensities were correlated with intracellular levels of GSH. The values (the relative GSH levels) are shown as mean ± SEM. The experiment was replicated at least three times. Different superscripts (a and b) represent treatment differences within panels (p < 0.05). Original magnification 200×.
Figure 4Effect of melatonin on mRNA expression of cell cycle-related genes in parthenogenetic zygotes (G1 stage). (A–C) The relative mRNA expression of cell cycle-related genes (P53, P21 and E2F1) in zygotes at G1 stage. The relative expression levels of mRNA were determined by the 2−△△ method and normalized against that of the reference gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase). All data are mean ± SEM from three replicates. Different superscripts (a, b and c) represent treatment differences within panels (p < 0.05).
Melatonin supplementation on parthenogenetic development of cryopreserved mouse MII oocytes.
| Groups | No. of Oocytes Activated | No. of Activated Oocytes Developed to | ||||
|---|---|---|---|---|---|---|
| 2-Cell Embryos (%) | 4-Cell Embryos (%) | Morula (%) | Blastocysts (%) | Hatched Blastocysts (%) | ||
| Control | 150 | 141 (94.00 ± 2.55) a | 140 (93.33 ± 0.87) a | 129 (86.00 ± 1.94) a | 100 (66.67 ± 1.32) a | 50 (33.33 ± 15.35) a |
| Vitrfication | 122 | 90 (73.77 ± 11.96) b | 97 (79.51 ± 11.96) b | 80 (65.57 ± 12.32) b | 41 (33.61 ± 6.54) b | 8 (6.56 ± 4.78) c |
| Vitrification + MT | 175 | 160 (91.43 ± 9.62) a | 165 (94.29 ± 10.06) a | 147 (84.00 ± 7.72) a | 100 (57.14 ± 16.17) a | 39 (22.29 ± 3.82) b |
The rates of 2-cell, 4-cell, morula, blastocysts and hatched blastocysts were calculated from the total number of activated oocytes. For instance, the rate of 2-cell embryos (%) = (No. of zygotes cleaved/No. of oocytes activated) × 100. The values indicate the mean ± SD of five independent experiments. Values with different superscripts (a, b and c) in the same column are significantly different (p < 0.05).
PCR primers used for SYBR green Q-PCR analysis.
| Gene | Assay ID | Primer seq (5′-3′) | Product Length | Tm (°C) |
|---|---|---|---|---|
|
| NM_001127233.1 | F: AGGATTGTGGCCTTCTTTGA | 126 | 62 |
| R: CAGATGCCGGTTCAGGTACT | ||||
|
| NM_001111099.2 | F: TGGAGATGAACTGGACAGCA | 84 | 62 |
| R: TGAAGTTGCCATCAGCAAAC | ||||
|
| NM_001291105.1 | F: CGAGTCCTATGCCTTCAACA | 159 | 62 |
| R: GAGTCCAGCCAGGAGATGAC | ||||
|
| NM_001289726.1 | F: AGAACATCATCCCTGCATCC | 124 | 62 |
| R: AGATCCACGACGGACACATT |
Figure 5Flowchart of experimental design. Control group: untreated mouse MII oocytes; Vitrification group: oocytes were vitrified by the open-pulled straw method without melatonin (MT) addition; Vitrification + MT group: oocytes were treated with MT at a final concentration of 10−9 mol/L in all the media used in the entire experiment; PA: parthenogenetic activation; IVC: in vitro culture; MT: melatonin.